4:52 PM
 | 
May 10, 2010
 |  BC Extra  |  Company News

Cipher gains on Cip-tramadol ER approval

Cipher Pharmaceuticals Inc. (TSX:DND) gained C$0.53 (48%) to C$1.63 on Monday after FDA approved Cip-tramadol ER to treat moderate to moderately severe chronic pain. Cipher, which is seeking a marketing partner, said the drug's launch is dependent on the outcome of...

Read the full 191 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >